Monoamine oxidase-mediated activation of MPTP and related compounds
Author:
Glover V.,Sandler M.
Publisher
Springer Netherlands
Reference43 articles.
1. Barbeau, A., Cloutier, T., Roy, M. et al., (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet, ii, 1213–16. 2. Birkmayer, W., Knoll, J., Riederer, P. et al. (1985) Increased life expectancy resulting from addition of 1-deprenyl to madopar treatment in Parkinson’s disease: a long term study. J. Neural Transm., 64, 113–27. 3. Birkmayer, W., Riederer, P., Youdim, M.B.H. and Linauer, W. (1975) Potential of antiakinetic effect after L-dopa treatment by an inhibitor of MAO B, 1-deprenyl. J. Neural Transm., 36, 303–23. 4. Burns, R.S., Chiueh, C.C., Markey, S.P. et al. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine.Proc. Natl. Acad. Sci, USA, 80, 4546–550. 5. Calne, D.B. and Peppard, R.F. (1987) Aging of the nigrostriatal pathway in humans. Can. J. Neurol. Sci., 14, 424–7.
|
|